Geode Capital Management, LLC Syndax Pharmaceuticals Inc Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,977,082 shares of SNDX stock, worth $27.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,977,082

Previous 1,910,623 3.48%

Holding current value

$27.3 Million

Previous $39.2 Million 2.98%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$17.93 - $24.81 $1.19 Million - $1.65 Million	66,459 Added 3.48%	1,977,082 $38.1 Million
Q2 2024 Aug 09, 2024	BUY	$18.82 - $23.79 $2.49 Million - $3.14 Million	132,075 Added 7.43%	1,910,623 $39.2 Million
Q1 2024 May 13, 2024	BUY	$19.71 - $24.57 $4.8 Million - $5.98 Million	243,493 Added 15.86%	1,778,548 $42.3 Million
Q4 2023 Feb 13, 2024	BUY	$11.39 - $21.67 $1.98 Million - $3.77 Million	174,135 Added 12.8%	1,535,055 $33.2 Million
Q3 2023 Nov 13, 2023	BUY	$14.52 - $21.77 $578,142 - $866,816	39,817 Added 3.01%	1,360,920 $19.8 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $1.81 Million - $2.09 Million	93,502 Added 7.62%	1,321,103 $27.7 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $2.61 Million - $3.67 Million	126,572 Added 11.5%	1,227,601 $25.9 Million
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $2.74 Million - $3.49 Million	132,900 Added 13.73%	1,101,029 $28 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $1.12 Million - $1.49 Million	60,273 Added 6.64%	968,129 $23.3 Million
Q2 2022 Aug 12, 2022	BUY	$13.64 - $19.48 $715,295 - $1.02 Million	52,441 Added 6.13%	907,856 $17.5 Million
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $1.35 Million - $2.01 Million	90,788 Added 11.87%	855,415 $14.9 Million
Q4 2021 Feb 11, 2022	BUY	$15.23 - $22.47 $478,328 - $705,715	31,407 Added 4.28%	764,627 $16.7 Million
Q3 2021 Nov 12, 2021	BUY	$13.87 - $19.8 $364,475 - $520,304	26,278 Added 3.72%	733,220 $14 Million
Q2 2021 Aug 13, 2021	BUY	$13.42 - $25.18 $1.88 Million - $3.53 Million	140,019 Added 24.7%	706,942 $12.1 Million
Q1 2021 May 12, 2021	BUY	$19.28 - $24.59 $2 Million - $2.55 Million	103,747 Added 22.4%	566,923 $12.7 Million
Q4 2020 Feb 12, 2021	BUY	$15.1 - $26.44 $772,561 - $1.35 Million	51,163 Added 12.42%	463,176 $10.3 Million
Q3 2020 Nov 13, 2020	SELL	$13.39 - $17.48 $35,845 - $46,793	-2,677 Reduced 0.65%	412,013 $6.08 Million
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $728,002 - $1.71 Million	81,432 Added 24.44%	414,690 $6.15 Million
Q1 2020 May 14, 2020	BUY	$6.65 - $12.03 $219,829 - $397,675	33,057 Added 11.01%	333,258 $3.66 Million
Q4 2019 Feb 13, 2020	BUY	$5.43 - $9.22 $75,819 - $128,738	13,963 Added 4.88%	300,201 $2.64 Million
Q3 2019 Nov 12, 2019	BUY	$7.47 - $10.76 $132,077 - $190,247	17,681 Added 6.58%	286,238 $2.14 Million
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $347,659 - $660,553	70,951 Added 35.91%	268,557 $2.5 Million
Q1 2019 May 14, 2019	BUY	$4.26 - $6.86 $74,153 - $119,412	17,407 Added 9.66%	197,606 $1.04 Million
Q4 2018 Feb 13, 2019	BUY	$3.6 - $8.42 $24,364 - $56,986	6,768 Added 3.9%	180,199 $801,000
Q3 2018 Nov 13, 2018	BUY	$6.33 - $8.08 $31,903 - $40,723	5,040 Added 2.99%	173,431 $1.4 Million
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $95,876 - $202,406	13,835 Added 8.95%	168,391 $1.18 Million
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $9,345 - $15,901	1,073 Added 0.7%	154,556 $2.2 Million
Q4 2017 Feb 13, 2018	BUY	$7.8 - $12.94 $177,863 - $295,070	22,803 Added 17.45%	153,483 $1.34 Million
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $51,022 - $59,589	4,681 Added 3.72%	130,680 $1.53 Million
Q2 2017 Aug 14, 2017	BUY	N/A	125,999	125,999 $1.76 Million

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $780M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Syndax Pharmaceuticals Inc Transaction History